Huntington's Disease Therapeutics - 佐思信息咨询

echinoidclapΒιοτεχνολογία

1 Δεκ 2012 (πριν από 8 χρόνια και 7 μήνες)

458 εμφανίσεις


全球亨廷顿氏病治疗市场研究报告
——
Huntington's Disease Therapeutics

联系购买电话:
〱M
-
㠲㠶㌴㠰U
公司名称:
佐思信息

公司地址:
北京市海淀区
苏州街
18
号院长远天地大厦
A2


1008
-
1
室(
100080



2010
-
4

摘要

This report analyzes the Global market for Huntington’s Disease
Therapeutics
in US$ Million. Annual estimates and forecasts are
provided for the period 2009 through 2015. The report profiles 37
companies including Alnylam Pharmaceuticals, Inc., Amarin Corporation,
Plc, Avicena Group, Inc., Biovail Corporation, Ceregene, Inc., Corte
x
Pharmaceuticals, Inc., H. Lundbeck A/S, Intellect Neurosciences
Incorporation, Medivation, Inc., NeuroSearch A/S, Prana Biotechnology
Limited, Raptor Pharmaceuticals Corp., Targeted Genetics Corporation,
Trophos SA, and Vertex Pharmaceuticals Incorporate
d. Market data and
analytics are derived from primary and secondary research. Company
profiles are mostly extracted from URL research and reported select
online sources.


Please note:
Reports are sold as single
-
site single
-
user licenses.
The delivery time
for hard copies is between 3
-
5 business days, as
each hard copy is custom printed for the organization ordering it.
Electronic versions require 24
-
48 hours as each copy is customized to
the client with digital controls and custom watermarks. The Publisher
uses digital controls protecting against copying and printing is
restricted to one full copy to be used at the same location.


The latest version of Adobe Acrobat Reader is required to view the
report. Upon ordering an electronic version, the Publisher wi
ll
provide a link to download the purchased report.


Prior to fulfillment of an order, the client will be required to sign
a document detailing the purchase terms for a publication from this
publisher.

目录及图表

. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS


Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY


1.

INDUSTRY OVERVIEW

A Prelude

Market Opportunity

Unmet Clinical Needs to Foster R&D Engine

Support Organizations Play An Instrumental Role

Improved Diagnostics Boosts HD Management

Competition in the Global HD Market is Nonexistent

Reimbursement Issu
es for HD

Effectiveness of Current HD Management Strategies

Affordability of Xenazine Will Be Key for Sustained Uptake

Off
-
Label Prescriptions

Select Off
-
Label Drugs Prescribed for Huntington’s Disease

Rising Interest in HD Drugs Development

Drug Dev
elopment Pipeline Reveals A Promising Picture

Public
-
Private Partnerships: A Shot in the Arm

Dimebon™ Candidacy As a Potent HD Drug Appear Doubtful

Drugs in Pipeline

HD
-
02

Huntexil™ (Pridopidine or ACR16)

OXIGON™

AMR101 (Miraxion™)

DR Cysteamine

P
BT2

Select Pipeline Drugs for Treatment of Huntington’s Disease As
of 2009

Promising Research Breakthroughs

Lundbeck Announces Successful Open
-
Label Results for Xenazine

UCLA Scientists Identify Molecular Switch to Check Huntington's
Disease in Mice

M
olecular Switch Capable of Blocking Huntington’s Disease
Identified

Novel Drug Targets Recognized for Huntington’s Disease

First Transgenic Monkey Model of Huntington's Disease Developed

Other Novel Approaches for HD Treatment

CERE
-
120

Cellular Delive
ry of Neurotropic Agents

Cogane

COPREXA

Histone Deacetylases (HDAC)

Melatonin, Coenzyme Q
-
Free Radical Scavengers

Minocycline
-

Caspase Inhibition

RNAi
-

RNA Interference

Small Molecule Inhibitor of Polyglutamine Interaction

TELOMICS™

2. AN OVERVI
EW OF HUNTINGTON’S DISEASE

Introduction

Historical Background

Prognosis

Stages of HD

Symptoms and Signs

Physical Symptoms

Emotional Symptoms

Mental Symptoms

Genetics of Huntington's Disease

Inheritance

Mechanism

Functions of HTT

Effects of mHT
T on Cells

Macroscopic Effects of mHTT

Diagnosis of HD

Clinical Diagnosis

Embryonic Diagnosis

Differential Diagnosis

Diagnostic Tests for Huntington's Disease

Confirmatory Diagnostic Test

Pre
-
symptomatic Diagnostic Test

Prenatal Diagnostic Test

T
reatment Options

Nutrition and Eating

Social Activity

Speech Therapy

Physical Therapy

Occupational Therapy

Medication

3. PRODUCT INTRODUCTIONS/CLINICAL TRIALS

Suven Life Sciences Secures Two Patents in the US

Medivation and Pfizer Begin Phase III
Trial of Dimebon

Alnylam and Medtronic Present New Preclinical Data on ALN
-
HTT

NeuroSearch Presents ACR16 as Novel Huntington’s Disease
Therapy

Raptor Pharmaceuticals Receives FDA Orphan Drug Designation for
Cysteamine

NeuroSearch Receives Approval fro
m EMEA for Huntexil™as New
Brand Name for Pridopidine

KeyNeurotek Pharmaceuticals Elucidates on Molecular
Pathomechanism of Huntingtin’s Mutation

NeuroSearch Begins Critical Phase III Program with ACR16

Avicena Proceeds to NIH Sponsored Phase III Trial
for

EnVivo Pharmaceuticals Progresses on Major HDACi Program

NeuroSearch Files CTA in Europe to Begin Clinical Phase III
Program with ACR16

4. RECENT INDUSTRY ACTIVITY

Alliance Pharma to Acquire Cambridge Laboratories

Alliance Pharma Concludes Distrib
ution Deal With Biovail

Lundbeck Acquires LifeHealth

Lundbeck Acquires Ovation

Biovail Purchases Global Rights for Tetrabenazine from
Cambridge

Raptor Pharmaceuticals, TorreyPines Concluded Merger

Cambridge Laboratories Enters into New Agreements for
Marketing
Xenazine® in North America

CHDI Foundation Inks Agreement with AMRI for Drug Discovery

Phytopharm Inks Agreement with CHDI Foundation to Evaluate
Cogane

NeuroSearch Repurchases Global Rights to ACR16

Raptor Pharmaceuticals Enters into Collabo
ration with Centre
Hospitalier Universitaire d'Angers for Phase II Clinical Trial

Targeted Genetics Acquires Full Rights from Sirna Therapeutics
to siRNA Development Program

Cambridge Laboratories Receives Marketing Approval for
Tetrabenazine from Agenci
a Espanola de Medicamentos y Productos
Sanitarios

Cambridge Laboratories Inks and Renews Agreements with Taiwan,
New Zealand, Finland and Australia

CHDI Inked Collaboration Agreements with Galapagos

Biovail Acquires Prestwick Pharmaceuticals

Ovation Ph
armaceuticals Acquires License to Commercialize
Xenazine® in the US

Aegera Therapeutics Inks License Agreement with Neurologix

Intellect Neurosciences Inks Agreement with CHDI Foundation to
Evaluate Potential of OXIGON™

Pipex Pharmaceuticals Entered into CRADA with Veterans Affairs
Medical Center for Evaluation of COPREXA

5. FOCUS ON SELECT PLAYERS

Alnylam Pharmaceuticals, Inc.

(USA)

Amarin Corporation, Plc (Ireland)

Avicena Group, Inc. (USA)

Biovail Corporation (Canada)

Ceregene, Inc. (USA)

Cortex Pharmaceuticals, Inc. (USA)

H. Lundbeck A/S (Denmark)

Intellect Neurosciences Incorporation (USA)

Medivation, Inc (USA)

Neu
roSearch A/S (Denmark)

Prana Biotechnology Limited (Australia)

Raptor Pharmaceuticals Corp. (USA)

Targeted Genetics Corporation (USA)

Trophos SA (France)

Vertex Pharmaceuticals Incorporated (USA)

6. GLOBAL MARKET PERSPECTIVE

Table 1: Global Current
and Future Analysis for Huntington's
Disease Therapeutics with Annual Revenue Figures in US$ Million
for Years 2009 through 2015 (includes corresponding Graph/Chart)

III. COMPETITIVE LANDSCAPE


Total Companies Profiled: 37

Region/Country Players

The Uni
ted States 19

Canada 3

Japan 1

Europe 12

France 1

Germany 1

The United Kingdom 2

Italy 1

Rest of Europe 7

Asia
-
Pacific (Excluding Japan) 2